MNK Overview
Upcoming Projects (MNK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MNK)
-
A Second Look at the efficacy of Stratagraft in thermal burn treatment
Ticker: MNK
Executed On: Jul 22, 2022 at 05:00 PM EDT -
A Final Take: Discussing the use of Terlipressin in treating HRS and how it compares to other vasopressors
Ticker: MNK
Executed On: Jul 22, 2022 at 03:00 PM EDT -
A third comparison of Acthar Gel and Cortrophin
Ticker: MNK
Executed On: Jul 22, 2022 at 11:00 AM EDT -
A Second Look: Comparing the use of Acthar Gel and Cortrophin
Ticker: MNK
Executed On: Jul 22, 2022 at 10:00 AM EDT -
Comparing Acthar Gel and Cortrophin in treating Multiple Sclerosis
Ticker: MNK
Executed On: Jul 22, 2022 at 08:30 AM EDT -
A Third Take: Discussing the use of Terlipressin in treating HRS and how it compares to other vasopressors
Ticker: MNK
Executed On: Jul 21, 2022 at 07:00 PM EDT -
Examining the efficacy of Stratagraft in thermal burn treatment
Ticker: MNK
Executed On: Jul 21, 2022 at 05:00 PM EDT -
A Second View: Discussing the use of Terlipressin in treating HRS and how it compares to other vasopressors
Ticker: MNK
Executed On: Jul 18, 2022 at 12:00 PM EDT -
Discussing the potential of Terlipressin in treating hepatorenal syndrome (HRS) and how it compares to other vasopressors
Ticker: MNK
Executed On: Jul 18, 2022 at 10:00 AM EDT
Upcoming & Overdue Catalysts (MNK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MNK)
-
Mallinckrodt (MNK) Receives CRL from the FDA for Terlipressin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)
Ticker: MNK
Occurred on: Sep 14, 2020 -
Mallinckrodt (MNK) to complete Phase 3 study of UVADEX® and ECP for Pediatric Patients with Graft Versus Host Disease in Q1 2017
Ticker: MNK
Occurred on: Oct 30, 2019 -
Mallinckrodt (MNK) to complete Phase 4 study of HP Acthar Gel in patients with multiple sclerosis in December 2018
Ticker: MNK
Occurred on: Feb 05, 2019 -
Mallinckrodt (MNK) to complete Phase 3 Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump
Ticker: MNK
Occurred on: Apr 17, 2018 -
Mallinckrodt to complete Phase 4 study of Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients in Q1 2017
Ticker: MNK
Occurred on: Aug 03, 2017 -
Mallinckrodt (MNK) to Initiate Phase 2 Study of Acthar Gel in Amyotrophic Lateral Sclerosis (ALS) in H1 2017
Ticker: MNK
Occurred on: Mar 03, 2017 -
Mallinckrodt (MNK) to complete Phase 2A study of Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Ticker: MNK
Occurred on: Nov 28, 2016 -
First Patient Enrolled in Mallinckrodt (MNK) Phase 4 Trial of H.P. Acthar Gel for Lupus
Ticker: MNK
Occurred on: Nov 14, 2016 -
First Patient Enrolled in Mallinckrodt (MNK) Phase 4 Trial of H.P. Acthar Gel for Rheumatoid Arthritis
Ticker: MNK
Occurred on: Nov 14, 2016 -
Mallinckrodt (MNK) to complete Phase 3 Study of Baclofen Injection (Intrathecal) in patients with severe spasticity in October 2016
Ticker: MNK
Occurred on: Oct 18, 2016 -
Mallinckrodt's Synacthen Depot Fast Track'd for Duchenne muscular dystrophy
Ticker: MNK
Occurred on: Aug 25, 2016 -
Mallinckrodt (MNK) to complete Phase 3 trial of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients in 2016
Ticker: MNK
Occurred on: Aug 10, 2016 -
First Patient Enrolled in Mallinckrodt Phase 3 CONFIRM Study to Assess Efficacy and Safety of Terlipressin in Hepatorenal Syndrome Type 1
Ticker: MNK
Occurred on: Jul 28, 2016 -
Mallinckrodt (MNK) to present at Deutsche Bank and Bank of America Healthcare conferences
Ticker: MNK
Occurred on: May 10, 2016 -
Mallinckrodt (MNK) to hold Q2 Earnings Call May 3
Ticker: MNK
Occurred on: May 03, 2016 -
Catalyst Pharma (CPRX) to Present at Annual BIO Investor Forum
Tickers: CPRX, MNK
Occurred on: Oct 21, 2015
Strategic Initiatives (MNK)
-
Mallinckrodt(MNK) Announces Extracorporeal Photopheresis (ECP) Research Collaboration Agreement With Transimmune AG
Tickers: MNK, Transimmune AG
Announcement Date: Feb 25, 2019
